This section captures essential information about the inventors and the funding sources that supported the development of the disclosed technology. Accurate metadata is critical for determining ownership rights, compliance obligations, and royalty distributions under institutional intellectual property policies and applicable research funding agreements.
Lead Inventor Full Legal Name
Lead Inventor Academic Title/Position
Lead Inventor Primary Department/Division
Lead Inventor Institutional Email Address
Lead Inventor Direct Phone Number
Lead Inventor Employee/Staff ID Number
Are there additional co-inventors who contributed to the conception and reduction to practice of this invention?
Grant Sponsor Metadata - List all grants that funded the research leading to this invention
Funding Agency/Organization Name | Grant/Contract Number | Grant Start Date | Grant End Date | Total Award Amount | Grant Program Officer Name | Grant Officer Contact Email | Percentage of Total Research Time on This Grant | |
|---|---|---|---|---|---|---|---|---|
Select all funding source categories that apply to this invention's development
Federal Government Research Grant
Federal Government Contract
State/Provincial Government Funding
Private Foundation Grant
Corporate Sponsored Research
Internal Institutional Seed Funding
Personal/Unfunded Research
Other External Funding
What percentage of the total development effort was funded by federal sources?
Did any inventors receive funding, materials, or resources from external entities not listed above (e.g., visiting scholar support, equipment loans)?
Do any inventors have existing consulting agreements, equity positions, or financial interests with companies that could potentially license this technology?
Provide a comprehensive technical description and commercial assessment of your invention. This information forms the foundation for patent drafting, prior art searches, and commercialization strategy. Be thorough in describing the problem, solution, and market opportunity to enable effective evaluation by technology transfer professionals and patent counsel.
Executive Summary of the Invention
Detailed Technical Description of the Invention
Specific Problem or Need Addressed by This Technology
Key Advantages and Benefits Over Existing Solutions
Primary Technology Category (select all that apply)
Biotechnology & Pharmaceuticals
Chemical & Materials Science
Medical Devices & Diagnostics
Software & Algorithms
Electrical & Electronics
Mechanical & Manufacturing
Energy & Clean Technology
Agriculture & Food Science
Environmental Technology
Nanotechnology
Quantum Technology
Other
Potential Applications and End-Use Markets
Current Technology Readiness Level (TRL) - Rate from 1 (basic principles observed) to 9 (system proven in operational environment)
Experimental Data, Prototypes, or Proof-of-Concept Results
Is a functional prototype or working model available for demonstration?
What is your preferred commercialization pathway?
License to Existing Company (outbound)
Start-up Company Formation (spin-out)
Open-Source Release (non-exclusive)
Continue Internal Development
Joint Venture Partnership
Uncertain - Seek TTO Guidance
Rate the following aspects of the invention's commercial potential
Very Low | Low | Moderate | High | Very High | |
|---|---|---|---|---|---|
Market size and growth potential | |||||
Competitive advantage sustainability | |||||
Technical feasibility and risk | |||||
Regulatory pathway complexity | |||||
Time to market | |||||
Scalability of manufacturing | |||||
Alignment with institutional priorities |
Known Competitors or Similar Technologies
Upload Supporting Technical Documents (lab notebooks, manuscripts, data sets, CAD drawings, software code repositories)
This section addresses compliance with the Bayh-Dole Act (or equivalent legislation) governing inventions made with federal funding. Accurate disclosure ensures proper electing of title, compliance with reporting requirements, and understanding of government rights. Failure to comply can result in loss of patent rights and institutional liability.
Was any portion of the research leading to this invention funded by a federal government agency?
Percentage of invention development directly attributable to federal funding (if applicable)
Has the invention been formally reported to the relevant federal funding agency within the required two-month period after disclosure to the institution?
I acknowledge and confirm understanding of the following Bayh-Dole Act requirements (check all to confirm)
Assess compliance status for each Bayh-Dole obligation
Non-Compliant | Partially Compliant | Compliant | Not Applicable | |
|---|---|---|---|---|
Invention disclosure to institution within required timeframe | ||||
Institutional election of title within statutory period | ||||
Patent application filing within one year (or extended period) | ||||
Government support acknowledgment in patent applications | ||||
Preference for US industry/manufacturing | ||||
Compliance with march-in rights provisions | ||||
Maintenance of proper laboratory records |
Does the invention involve national security, sensitive technology, or export-controlled subject matter?
Describe any existing or planned collaborations with foreign institutions, researchers, or companies regarding this technology
Government Rights and License Summary
Funding Agency | Grant Number | Government License Required? | License Type/Scope | Invention Report Date to Agency | Patent Application Filing Deadline | |
|---|---|---|---|---|---|---|
Has the institution received any formal march-in rights notices or government inquiries regarding this or related technology?
Complete disclosure of all prior public disclosures is critical for patentability assessment. Under patent law, public disclosures can trigger statutory bars and destroy novelty. This section enables technology transfer offices and patent counsel to evaluate grace period applicability, design around strategies, and assess the strength of potential patent claims. Include all forms of disclosure regardless of perceived significance.
Have you publicly disclosed the invention in any form before the earliest conception date recorded?
Has a formal patentability or prior art search been conducted for this invention?
List any known patents, patent applications, or publications that you believe may be relevant prior art
Has the invention been discussed with any external companies or potential commercial partners under a confidentiality agreement?
Are there any third-party materials, background IP, or jointly-owned technology incorporated into this invention?
Has there been any offer for sale, commercial use, or revenue generation using this technology?
What is the earliest date you consider the invention to have been conceived?
What is the earliest date you consider the invention to have been reduced to practice (e.g., working prototype, successful experiment)?
Describe any internal laboratory notebooks, electronic records, or other documentation that establish conception and reduction to practice dates
This final section documents institutional review, risk assessment, and formal acceptance of the invention disclosure by authorized technology transfer and legal personnel. This formal sign-off triggers the intellectual property protection workflow, commercialization strategy development, and establishes the official record of institutional ownership and management responsibilities.
Primary Technology Transfer Office Case Manager Assigned
Date of Disclosure Submission to TTO
Has a formal intellectual property assignment agreement been executed by all inventors?
Institutional Ownership Determination
Institution Sole Owner - No external claims
Institution Co-Owner with Federal Government
Institution Co-Owner with Corporate Sponsor
Institution Co-Owner with Other University
Ownership Under Dispute/Review
Third Party Has Principal Rights
Technology Transfer Office Risk Assessment and Viability Matrix
Poor | Fair | Good | Excellent | Outstanding | |
|---|---|---|---|---|---|
Patentability prospects | |||||
Commercial potential | |||||
Market readiness | |||||
Regulatory pathway clarity | |||||
Competitive landscape intensity | |||||
Freedom to operate risk | |||||
Inventor commitment to commercialization | |||||
Alignment with institutional mission |
Has university legal counsel reviewed this disclosure for contractual and legal compliance?
Does this invention require specialized legal review (e.g., export control, FDA regulatory, data privacy)?
Action Items and Next Steps - TTO to Complete
Action Item | Responsible Party | Target Completion Date | Priority (1=Low, 5=Critical) | Completed? | |
|---|---|---|---|---|---|
Initial prior art search | TTO Patent Coordinator | 2/15/2025 | |||
Inventor interviews for patent drafting | External Patent Counsel | 3/1/2025 | |||
Market analysis and licensing strategy | TTO Licensing Manager | 3/15/2025 | |||
Are all inventors committed to actively participating in the commercialization process (e.g., responding to patent counsel, attending marketing meetings, supporting licensee discussions)?
TTO Internal Notes and Commercialization Strategy Recommendations
Lead Inventor Signature - Certifying accuracy and completeness of disclosure
Technology Transfer Office Director Signature - Accepting disclosure for institutional IP management
University Legal Counsel Signature - Confirming legal review and risk assessment